Use of il-23 and il-17 antiagonists to treat autoimmune ocular inflammatory disease

Abstract

Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.

What is claimed is: 
     
         1 . A method of treating a patient for an autoimmune ocular inflammatory disease (AOID), comprising administering to the patient an IL-23 antagonist. 
     
     
         2 . The method of  claim 1 , wherein the IL-23 antagonist is a monoclonal antibody or a monoclonal antibody fragment that binds to and inhibits the activity of IL-23p19 or IL-23R. 
     
     
         3 . The method of  claim 1 , wherein a specified dose of the IL-23 antagonist is administered at a specified interval during a first treatment period, wherein the specified interval is once per day, once per week, 2 to 7 times per week, once every other week, and once per month. 
     
     
         4 . The method of  claim 1 , wherein the duration of the first treatment period is between three months and two years. 
     
     
         5 . The method of  claim 1 , wherein the duration of the first treatment period is between six months and one year. 
     
     
         6 . The method of  claim 1 , wherein the dose of the IL-23 antagonist is gradually reduced during a second treatment period that begins upon the end of the first treatment period. 
     
     
         7 . The method of  claim 1 , wherein the AOID is uveitis. 
     
     
         8 . A manufactured drug product for treating an autoimmune inflammatory disease (AOID), which comprises
 (a) a first pharmaceutical formulation comprising an IL-17 antagonist; and   (b) a second pharmaceutical formulation comprising an IL-23 antagonist.   
     
     
         9 . The manufactured drug product of  claim 8 , wherein the IL-17 antagonist is a monoclonal antibody or monoclonal antibody fragment binds to and inhibits the activity of IL-17 or IL-17RA and the a monoclonal antibody or a monoclonal antibody fragment that binds to and inhibits the activity of IL-23p19 or IL-23R. 
     
     
         10 . The manufactured drug product of  claim 8 , wherein the AOID is uveitis.